Meanwhile, the S&P BSE Sensex was down 15.97 points, or 0.06%, to 28,645.61.

High volumes were witnessed on the counter. On the BSE, 33.95 lakh shares were traded on the counter so far as against the average daily volumes of 5.02 lakh shares in the past one quarter. The stock had hit a high of Rs 52.40 and a low of Rs 49.30 so far during the day.

The stock had hit a 52-week high of Rs 58.30 on 6 October 2016 and a 52-week low of Rs 33.45 on 1 March 2016. The stock had outperformed the market over the past one month till 20 February 2017, advancing 23.92% compared with the Sensex's 6.02% rise. The scrip had also outperformed the market over the past one quarter advancing 13.92% as against the Sensex's 9.6% rise.

The small-cap company has equity capital of Rs 40.93 crore. Face value per share is Rs 1.

Shares of Marksans Pharma rallied 25.86% in two trading sessions from its close of Rs 40.60 on 17 February 2017, after the company announced during market hours yesterday, 20 February 2017 that its Goa plant's inspection by UK MHRA from 14th February 2017 to 17 February 2017 was completed without any critical observations. The stock had rallied 19.95% to settle at Rs 48.70 yesterday, 20 February 2017 post announcement.

Marksans Pharma's consolidated net profit fell 37% to Rs 11.30 crore on 1% decrease in net sales to Rs 215.24 in Q3 December 2016 over Q3 December 2015.

Marksans Pharma is a global pharmaceutical company. It is engaged in research & development (R&D) and offers CRAMS (contract research and manufacturing services) to global pharmaceutical companies.